Pasithea Therapeutics Says Interim Phase 1 Data Show Tumor Drug Candidate's Efficacy, Safety; Shares Rise Pre-Bell

MT Newswires Live09-26

Pasithea Therapeutics (KTTA) said Thursday that interim data from a phase 1 study showed that its experimental drug, PAS-004, was effective and safe in treating neurofibromatosis type 1 and other cancer indications.

The company said PAS-004's long half-life of about 70 hours enables once-daily or less frequent oral dosing compared with previous versions of the drug, which required twice-daily dosing and exhibited short half-lives.

Pasithea also said that the drug's pharmacokinetic profile indicated consistent plasma levels at a steady state, which may reduce the risk of toxicity related to peak concentrations.

The drug developer said that the study results support the advancement of PAS-004 into clinical trials for treating cutaneous and plexiform neurofibromas in NF1, as well as other MAPK-driven conditions.

The company plans to provide additional trial updates periodically as the trial progresses.

Shares of the company rose more than 63% in premarket activity Thursday.

Price: 6.2800, Change: +2.44, Percent Change: +63.33

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2470201787?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-26 19:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2470201787","market":"us","top_or_hot":-1,"title":"Pasithea Therapeutics Says Interim Phase 1 Data Show Tumor Drug Candidate's Efficacy, Safety; Shares Rise Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Pasithea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (KTTA) said Thursday that interim data from a phase 1 study showed that its experimental drug, PAS-004, was effective and safe in treating neurofibromatosis type 1 and other cancer indications.</p><p>The company said PAS-004's long half-life of about 70 hours enables once-daily or less frequent oral dosing compared with previous versions of the drug, which required twice-daily dosing and exhibited short half-lives.</p><p>Pasithea also said that the drug's pharmacokinetic profile indicated consistent plasma levels at a steady state, which may reduce the risk of toxicity related to peak concentrations.</p><p>The drug developer said that the study results support the advancement of PAS-004 into clinical trials for treating cutaneous and plexiform neurofibromas in NF1, as well as other MAPK-driven conditions.</p><p>The company plans to provide additional trial updates periodically as the trial progresses.</p><p>Shares of the company rose more than 63% in premarket activity Thursday.</p><p>Price: 6.2800, Change: +2.44, Percent Change: +63.33</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pasithea Therapeutics Says Interim Phase 1 Data Show Tumor Drug Candidate's Efficacy, Safety; Shares Rise Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPasithea Therapeutics Says Interim Phase 1 Data Show Tumor Drug Candidate's Efficacy, Safety; Shares Rise Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-26 19:56 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pasithea Therapeutics (KTTA) said Thursday that interim data from a phase 1 study showed that its experimental drug, PAS-004, was effective and safe in treating neurofibromatosis type 1 and other ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KTTA","symbol_name":"Pasithea Therapeutics Corp.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2470201787","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470201787","pubTimestamp":1727351817,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Pasithea Therapeutics  said Thursday that interim data from a phase 1 study showed that its experimental drug, PAS-004, was effective and safe in treating neurofibromatosis type 1 and other cancer indications.The company said PAS-004's long half-life of about 70 hours enables once-daily or less frequent oral dosing compared with previous versions of the drug, which required twice-daily dosing and exhibited short half-lives.Pasithea also said that the drug's pharmacokinetic profile indicated consistent plasma levels at a steady state, which may reduce the risk of toxicity related to peak concentrations.The drug developer said that the study results support the advancement of PAS-004 into clinical trials for treating cutaneous and plexiform neurofibromas in NF1, as well as other MAPK-driven conditions.The company plans to provide additional trial updates periodically as the trial progresses.Shares of the company rose more than 63% in premarket activity Thursday.Price: 6.2800, Change: +2.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KTTA":"Pasithea Therapeutics Corp.","BK4139":"生物科技","LENZ":"Therapeutics"},"translate_title":"Pasithea Therapeutics表示，中期1期数据显示了肿瘤候选药物的有效性和安全性；盘前股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KTTA":1,"LENZ":1},"content_text":"Pasithea Therapeutics (KTTA) said Thursday that interim data from a phase 1 study showed that its experimental drug, PAS-004, was effective and safe in treating neurofibromatosis type 1 and other cancer indications.The company said PAS-004's long half-life of about 70 hours enables once-daily or less frequent oral dosing compared with previous versions of the drug, which required twice-daily dosing and exhibited short half-lives.Pasithea also said that the drug's pharmacokinetic profile indicated consistent plasma levels at a steady state, which may reduce the risk of toxicity related to peak concentrations.The drug developer said that the study results support the advancement of PAS-004 into clinical trials for treating cutaneous and plexiform neurofibromas in NF1, as well as other MAPK-driven conditions.The company plans to provide additional trial updates periodically as the trial progresses.Shares of the company rose more than 63% in premarket activity Thursday.Price: 6.2800, Change: +2.44, Percent Change: +63.33","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2470201787"}